Novo Nordisk Quantum
About
Novo Nordisk explores quantum computing applications for pharmaceutical research and drug discovery, investigating quantum algorithms for molecular simulation, protein folding prediction, and drug optimization that could accelerate diabetes and obesity treatment development. The company researches quantum machine learning for analyzing clinical trial data, patient stratification, and personalized medicine approaches, exploring how quantum computing could enhance pharmaceutical research capabilities in endocrinology and metabolic diseases. Novo Nordisk collaborates with quantum computing companies and academic institutions to leverage quantum advantages in computational chemistry, biomarker discovery, and therapeutic development processes, contributing to the pharmaceutical industry's adoption of quantum technologies for improving drug discovery timelines and therapeutic outcomes in diabetes care and chronic disease management.
Categories
Key People
Lars Fruergaard Jørgensen (CEO), Camilla Sylvest (Chief Strategy Officer)
Request Information
Interested in Novo Nordisk Quantum? Get pricing, demos, or technical details.
Request Information
Get in touch with Novo Nordisk Quantum about your project.
Claim This Profile
Are you from Novo Nordisk Quantum? Verify your association to update your listing and receive notifications.
Claim Your Profile
Verify you represent Novo Nordisk Quantum to update your listing.
Quick Facts
Links
Location
Loading map...
Stay Updated
Get the latest quantum computing news delivered to your inbox.